Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 20th 2014

Bayer's Xofigo Gains NICE Approval

The National Institute for Health and Care Excellence has issued draft guidelines on using the drug in prostate cancer patients.

December 17th 2014

Treatment Decisions and Unmet Needs

December 17th 2014

Anti-Androgens and Combination Regimens in CRPC

December 17th 2014

Early Indication of Androgen Deprivation Resistance

December 17th 2014

Diagnostic and Prognostic Biomarkers

December 17th 2014

Episode 3 - The CHAARTED Study-Treatment of CRPC with Docetaxel

December 17th 2014

Episode 2 - Variability in Disease Course and Treatment Approach

December 17th 2014

Episode 1 - Defining and Detecting CRPC

December 17th 2014

AJMC Session Traces Evolution of ACO Growth, Mental Health Delivery Models

How do ACOs reach the point of delivering both savings and better care? The recent online session of the ACO and Emerging Healthcare Delivery Coalition, sponsored by The American Journal of Managed Care, covered how ACOs evolve, how that process applies to oncology care, and how managed care can benefit from a better model for mental health delivery.

December 16th 2014

Alex Bastian Strives to Define Value in Care Better

In order to reign in high costs of care in oncology, the healthcare community needs to be able to define value better, according to Alex Bastian, MBA, senior vice president at GfK.

December 15th 2014

UnitedHealth Launches Bundled Payment Program at MD Anderson

The pilot, which will has been launched for head and neck cancer patients, will include quality measures to ensure adequate patient care.

December 14th 2014

After Astra, Pfizer Taps Other Immuno-Oncology Markets

With the immuno-oncology field getting more intense, Pfizer continues its struggle to gain a foothold in the field. Following unsuccessful attempts to bid for AstraZeneca, Pfizer has now signed a deal with a Belgian company, iTeos Therapeutics.

December 13th 2014

How Should E-Cigarettes Be Regulated?

Should e-cigarettes be regulated he same way as cigarettes? Should marketing and sales restrictions be the same? Policy and health experts chime-in.

December 13th 2014

Hopkins Adapts to Prevent Cancer Risk of Uterine Morcellation

Just prior to the FDA guidance on the use of power morcellators, Johns Hopkins made public a new care plan for managing fibroids or hysterectomies in women over age 50 years.

December 13th 2014

Making a Case for Biomarkers in Cancer Immunotherapy

Immune response boosters in oncology, approved for melanoma so far, are being evaluated in several different cancer types. While the drugs perform well, there is a definite need to identify responsive patient cohorts.

December 13th 2014

One For Choosing Wisely in Breast Cancer

A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.

December 12th 2014

Oncotype DX DCIS Can Predict Recurrence in Women With DCIS

Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery for DCIS.

December 12th 2014

Cyramza Receives Extended Approval for Advanced NSCLC

The combination of (Cyramza) ramucirumab with docetaxel was today approved by the FDA for the treatment of advanced non-small cell lung cancer and in those who have been treated with platinum-based therapy.

December 12th 2014

Nashville Star Charles Esten Shares Personal Experience in Battling Rare Blood Disease

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was 2-and-a-half, shares the challenging and painful experiences of battling the disease.

December 11th 2014

Quality of End-of-Life Care for Cancer Patients: Does Home Hospice Care Matter?

Netta Bentur, PhD Shirli Resnizky, MA Ran Balicer, MD Tsofia Eilat-Tsanani, MD

Palliative principles were applied to the care of more HH patients than non-HH patients, but no differences were found in their utilization of healthcare services.

December 11th 2014

Validating Electronic Cancer Quality Measures at Veterans Health Administration

Jeremy B. Shelton, MD, MSHS Ted A. Skolarus, MD, MPH Diana Ordin, MD, MPH Jennifer Malin, MD, PhD AnnaLiza Antonio, MS Joan Ryoo, MD, MSHS Christopher S. Saigal, MD

Even in a fully integrated healthcare system, only 28% of cancer quality measures could be validated by using electronically available data.

December 11th 2014

Slow Adoption of Less Costly, Patient-Preferred Radiation Therapy

Laura Joszt, MA

A majority of breast cancer patients in the US are receiving longer radiation therapy than is necessary and compared with their counterparts in other countries, according to a new study published in JAMA.

December 9th 2014

SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML

Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.

December 9th 2014

EPIC Trial Shows Ponatinib Effective in CML

On Monday, the third day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9, in San Francisco, Jeffrey H. Lipton, MD, PhD, chief, presented results from the EPIC trial, evaluating ponatinib in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

December 9th 2014

CML Updates: Defining MMR and Results of the DASISION Trial

On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.

December 8th 2014

Giora Sharf Discusses Ways to Represent the CML Patient Voice

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

December 8th 2014

Dr Susanne Saussele Defines When Patients With CML Should Change Therapy

Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.

December 8th 2014

Evaluating Safety, Efficacy, and Outcomes of TKIs in CML

A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.

December 8th 2014

Jan Geissler Explains Differing Perceptions for Living With CML

Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.

December 8th 2014

Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.

...

143 144 145 146 147 148 149 150 151

...

184 >